Evidence map›Paper›PMID 35769567›Full record

ArticleFrontiers in allergy2022

White Paper on European Patient Needs and Suggestions on Chronic Type 2 Inflammation of Airways and Skin by EUFOREA.

Louise De Prins, Ulrike Raap, Tara Mueller, Peter Schmid-Grendelmeier, Christiane H Haase, Vibeke Backer, Wytske Fokkens, Linda B Benoist, Emmanuel Prokopakis, Claire Hopkins and 12 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Frontiers in allergy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Editorial: 2022 in review: rhinology.Frontiers in allergy · 2024
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors at 10 institutions in 7 countries.

Louise De PrinsDepartment of Otorhinolaryngology, Head and Neck Surgery, Universitair Ziekenhuis Leuven, Leuven, Belgium.
Ulrike RaapDivision of Experimental Allergology and Immunodermatology, University of Oldenburg, Oldenburg, Germany.
Tara MuellerDivision of Experimental Allergology and Immunodermatology, University of Oldenburg, Oldenburg, Germany.
Peter Schmid-GrendelmeierAllergy Unit, Department of Dermatology, University Hospital of Zürich, Zürich, Switzerland.
Christiane H HaaseDepartment of Otorhinolaryngology, Head and Neck Surgery and Audiology, Rigshospitalet, Copenhagen, Denmark.
Vibeke BackerDepartment of Otorhinolaryngology, Head and Neck Surgery and Audiology, Rigshospitalet, Copenhagen, Denmark.
Wytske FokkensDepartment of Otorhinolaryngology, Head and Neck Surgery, Academic Medical Center (AMC), Amsterdam, Netherlands.
Linda B BenoistDepartment of Otorhinolaryngology, Head and Neck Surgery, Academic Medical Center (AMC), Amsterdam, Netherlands.
Emmanuel ProkopakisDepartment of Otorhinolaryngology-Head and Neck Surgery, School of Medicine, University of Crete, Heraklion, Greece.
Claire HopkinsGuy's and St Thomas' Hospital, London Bridge Hospital, London, United Kingdom.
Nele ClaeysDepartment of Otorhinolaryngology, Head and Neck Surgery, Universitair Ziekenhuis Leuven, Leuven, Belgium.
Thijs TeelingDepartment of Otorhinolaryngology, Head and Neck Surgery, Universitair Ziekenhuis Leuven, Leuven, Belgium.
Lindsay CypersDepartment of Otorhinolaryngology, Head and Neck Surgery, Universitair Ziekenhuis Leuven, Leuven, Belgium.
Leen CoolsDepartment of Otorhinolaryngology, Head and Neck Surgery, Universitair Ziekenhuis Leuven, Leuven, Belgium.
Leif H BjermerDepartment of Otorhinolaryngology, Head and Neck Surgery, Universitair Ziekenhuis Leuven, Leuven, Belgium.
Zuzana DiamantDepartment of Otorhinolaryngology, Head and Neck Surgery, Universitair Ziekenhuis Leuven, Leuven, Belgium.
Ulrich WahnDepartment of Otorhinolaryngology, Head and Neck Surgery, Universitair Ziekenhuis Leuven, Leuven, Belgium.
Glenis ScaddingDepartment of Otorhinolaryngology, Head and Neck Surgery, Universitair Ziekenhuis Leuven, Leuven, Belgium.
Claus BachertUpper Airways Research Laboratory, Department of Otorhinolaryngology, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.
Sunni R PatelDepartment of Otorhinolaryngology, Head and Neck Surgery, Universitair Ziekenhuis Leuven, Leuven, Belgium.
Elizabeth Van StaeyenDepartment of Otorhinolaryngology, Head and Neck Surgery, Universitair Ziekenhuis Leuven, Leuven, Belgium.
Peter HellingsDepartment of Otorhinolaryngology, Head and Neck Surgery, Universitair Ziekenhuis Leuven, Leuven, Belgium.
London Bridge Hospital · GBUniversity of Crete · GRGhent University · BERigshospitalet · DKAcademic Medical Center · NLKlinikum Oldenburg · DEUniversity Hospital of Zurich · CHCarl von Ossietzky Universität Oldenburg · DESt Thomas' Hospital · GBUniversitair Ziekenhuis Leuven · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Type 2 inflammation underlies the chronicity of disease in subgroups of patients with asthma, chronic rhinosinusitis with nasal polyps (CRSwNP) and atopic dermatitis (AD), that often co-exist. Although several studies have investigated the unmet needs of asthma, AD and CRSwNP as such, little is known about the similarities and differences in experiences and perspectives of the current management of patients with comorbid Type 2 inflammatory diseases. Aims: To improve insight into the common and organ-specific needs of patients with Type 2 inflammation and comorbidities, allowing the formulation of recommendations to better address these needs in the future. Methodology: This qualitative study was conducted between July 2021 and December 2021 using semi-structured face-to-face or telephone interviews with patients suffering from year-long severe chronic Type 2 inflammation and at least one co-morbid inflammatory condition. Seven participating academic centers in Europe interviewed asthma (Copenhagen and Leuven), CRSwNP (London, Amsterdam and Crete) and/or AD (Oldenburg and Zurich) patients on patient characteristics, disease severity, shortcomings of current care pathways and suggestions for improvement of care. Transcripts were analyzed using an inductive thematic analysis approach. Results: Eighty-one patients with severe Type 2 inflammation and comorbidities were interviewed. Similar needs were recognized by patients with Type 2 inflammation, with both a lack of coordination in care and a lack of a real cure reported as being most frustrating. However, several needs are specific to asthma, CRSwNP and AD. Suggestions for improvement of care were generic across diseases, such as the implementation of a multidisciplinary approach, the improved facilitation of access to better treatments, the increase of general awareness on disease burden, and better educational programs for healthcare providers and patients. Of note, patients with CRSwNP also stated the need for alternatives to sinus surgery, whereas patients with asthma requested better medical care to prevent exacerbations and patients with AD would warmly welcome the reimbursement of emollients. Conclusion: Patients with asthma, CRSwNP and AD have shared unmet needs that need to be addressed by physicians, the academic community and health policy makers. This survey provides unique recommendations made by patients for the implementation of better care.

Indexed as

asthmaatopic dermatitischronic rhinosinusitisnasal polypsquality of lifeType 2 inflammationunmet needs

Identifiers

PMID35769567
PMCPMC9234878
OpenAlexW4281776049

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.